Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: harrowinc.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/11/2025 | $76.00 | Overweight | Cantor Fitzgerald |
6/12/2025 | $62.00 | Buy | BTIG Research |
6/10/2025 | Outperform | William Blair | |
2/6/2025 | $57.00 | Buy | H.C. Wainwright |
12/4/2024 | $73.00 → $69.00 | Buy | B. Riley Securities |
4/11/2024 | $24.00 | Buy | Craig Hallum |
9/8/2022 | $17.00 | Buy | B. Riley Securities |
10/14/2021 | $16.00 | Buy | B. Riley Securities |
9/24/2021 | $15.00 | Buy | Aegis Capital |
7/2/2021 | $14.25 | Buy | Ladenburg Thalmann |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - HARROW, INC. (0001360214) (Issuer)
3 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
8-K/A - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
10-Q - HARROW, INC. (0001360214) (Filer)
Fastest customizable press release news feed in the world
NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. The closing of this acquisition is subject to customary closing conditions, including approval by Melt stockholders, excluding Harrow and Harrow-affiliated parties. Melt's lead investigational therapy, MELT-300, is a patented, sublingually delivered formulation of a fixed dose o
HAFA to Expand Harrow's Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of Harrow Access for All ("HAFA"), expanding Harrow's commitment to make it easier and more affordable for patients to access Harrow's full range of branded, generic, and compounded ophthalmic medications. HAFA builds on the success of the VEVYE® Access for All ("VAFA") initiative, which launched in March 2025 with a strong reception from both physician
NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will also be webcast live and instructions for accessing the webcast are below. Harrow's Investor & Analyst Day will include a comprehensive overview of Harrow's business, featuring presentations from the Company's leadership team covering the full scope of Harrow's commercial portfolio, pipeline, and long-term vision. In addition, the program will include presentations from renowned physici
NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the "Offering") of $250.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The Offering
Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has commenced a private offering (the "Offering") of $250.0 million aggregate principal amount of senior unsecured notes due 2030 (the "2030 Notes"), subject to market and certain other conditions. The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restrict
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the "Investors" s
NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright's 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually. Harrow's Chief Executive Officer, Mark L. Baum, and Chief Financial Officer, Andrew Boll, will participate in a fireside chat on Wednesday, August 13 at 8:30 a.m. Eastern time. In addition, Mark will participate in a panel discussion on "Novel Treatments for Front-of-the-Eye Indications" at 1 p.m. Eastern time. Both the fireside chat and the panel will be webcast live and can be found on the Company's w
NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 12, 2025, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on the "Investors" page of Harrow'
Harrow to assume full commercial responsibility for BYOOVIZ® and OPUVIZ™ by the end of 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter "Samsung Bioepis") to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEAii (aflibercept) — two of the most widely used anti-VEGF therapies for retinal diseases. BYOOVIZ has been commercialized
Harrow will assume full commercial responsibility for BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) upon full transition of Biogen's commercialization rights back to Samsung Bioepis by the end of 2025 BYOOVIZ, approved by the FDA in September 2021 as the first ophthalmology biosimilar in the US, has been commercially available since June 2022 OPUVIZ was approved by the FDA in May 2024 Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (NASDAQ:HROW), for Samsung Bioepis' ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUC
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW HEALTH, INC. (0001360214) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00
BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00
William Blair initiated coverage of Harrow with a rating of Outperform
H.C. Wainwright initiated coverage of Harrow with a rating of Buy and set a new price target of $57.00
B. Riley Securities reiterated coverage of Harrow with a rating of Buy and set a new price target of $69.00 from $73.00 previously
Craig Hallum initiated coverage of Harrow with a rating of Buy and set a new price target of $24.00
B. Riley Securities resumed coverage of Harrow Health with a rating of Buy and set a new price target of $17.00
B. Riley Securities resumed coverage of Harrow Health with a rating of Buy and set a new price target of $16.00
Aegis Capital initiated coverage of Harrow Health with a rating of Buy and set a new price target of $15.00
Ladenburg Thalmann initiated coverage of Harrow Health with a rating of Buy and set a new price target of $14.25
Live Leadership Updates
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company's portfolio of new and existing products. Dr. Mannebach's successful 30-year career in the pharmaceutical industry, much of which was focused in ophthalmology, includes leadership roles in regulatory affairs, quality assurance, program management and pharmaceutical product development. "Dr. Mannebach brings to Harrow decades of regulatory and clinical expertise and leadership –specifically in ophth
Live finance-specific insights
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the "Investors" s
NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 12, 2025, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on the "Investors" page of Harrow'
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. This press release features multimedia. View the full release here: https://www.busin
First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th
Fourth-Quarter, Full-Year 2024, and Recent Highlights: Record revenues of $66.8 million for Q4 2024, an 84% increase over Q4 2023 Revenues of $199.6 million for FY 2024, a 53% increase over FY 2023 GAAP net income of $6.8 million for Q4 2024, for a GAAP net loss of $(17.5) million for FY 2024 Adjusted EBITDA of $22.5 million for Q4 2024, leading to Adjusted EBITDA of $40.3 million for FY 2024 IHEEZO® unit demand and VEVYE® prescriptions for Q4 2024 each increased over 40% over Q3 2024 VEVYE® Access for All program expected to drive continued market share expansion in 2025 TRIESENCE® transitional pass-through approved, significantly increasing addressable market opportunity H
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 28, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financial results for the year ended December 31, 2024, on Thursday, March 27, 2025, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, March 28, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live co
Company Expects to Provide Revised Dates for Release of Audited Financial Results, Conference Call, and Letter to Stockholders Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced unaudited preliminary financial results for the fourth quarter and year ended December 31, 2024, as well as revenue guidance for 2025. Although Harrow was initially scheduled to release its audited financial results today, the Company's new independent auditor requires additional time to audit Harrow's financial presentation. As a result, Harrow is delaying its earnings release, conference call and Annual Report on Form 10-K filing. The change in the date of the filing of
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 18, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2024, on Monday, March 17, 2025, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 18, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conferen
Third Quarter 2024 and Recent Selected Highlights: Revenues increased 44% from $34.3 million in the prior-year quarter to $49.3 million GAAP net loss of $(4.2) million Adjusted EBITDA of $8.8 million Operating cash flow of $3 million Cash and cash equivalents of $72.6 million as of September 30, 2024 VEVYE® total prescriptions up 55% over the second quarter of 2024 IHEEZO® customer unit demand volume up 15% over the second quarter of 2024 TRIESENCE® October 2024 relaunch underway Expansion of access and affordability through multiple new partnerships First major Medicare Part D win for VEVYE with major plan sponsors Fourth quarter revenue indicates meaningfu
This live feed shows all institutional transactions in real time.
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G - HARROW, INC. (0001360214) (Subject)
SC 13G - HARROW, INC. (0001360214) (Subject)
SC 13D/A - HARROW HEALTH, INC. (0001360214) (Subject)
SC 13G/A - HARROW HEALTH, INC. (0001360214) (Subject)
SC 13G - HARROW HEALTH, INC. (0001360214) (Subject)